GE Healthcare recalled 173 units of the Carescape Central Station on September 5, 2025. The device may enter a continuous reboot cycle, risking loss of patient monitoring. This issue occurs when 118 to 120 stations connect to the network.
GE HealthCare has identified an issue affecting Carescape" Central Station (CSCS) with software version V3.0.5, which can cause the system to enter a continuous reboot cycle. If this occurs, a loss of central monitoring of connected patients could result. This issue occurs only when the number of central stations connected to the network is 118, 119 or 120.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Wipro GE Healthcare Private Ltd. or your healthcare provider for instructions. Notification method: Letter
The recalled product is the GE Healthcare Carescape Central Station (CSCS) V3 MAS800 Desktop, software version V3.0.5, part number 5867474-04. It was distributed worldwide.
The device may enter a continuous reboot cycle, leading to loss of central patient monitoring. This risk arises only when 118 to 120 Carescape Central Stations are connected to the network.
No specific incidents or injuries have been reported related to this issue as of the recall date. The risk remains high due to the potential for loss of monitoring.
Healthcare providers and patients should stop using the device immediately. Follow the manufacturer's recall instructions and contact Wipro GE Healthcare for further guidance.
For assistance, contact Wipro GE Healthcare Private Ltd. or your healthcare provider. More details are available on the FDA's recall page.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.